Late breaking news presentation slides
Legacy Healthcare is developing transformative medicines for the treatment of autoimmune and inflammatory diseases, with an immune-sparing mode of action, allowing safe chronic use.
Our first drug, Coacillium, achieves this goal.
Coacillium cutaneous solution has been filed for approval with EMA for the treatment of alopecia areata, a debilitating autoimmune dermatological disease with intense psychological impact on all patients, especially in children.
News & events
Clinical data presentation
"Botanicals in pharma:
Potential and pitfalls"
"Positive Top-Line Results
from Phase 2/3 Trial"